LM
RAPT

Luminus Management’s RAPT Therapeutics RAPT Stock Holding History

Luminus Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-33,409
Closed -$5.68M – 87
2020
Q1 		$5.68M Buy
+33,409
New +$7.61M 0.59% 51

Other funds holding RAPT

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Luminus Management's RAPT Position: Q2 2020 in Review

Luminus Management sold out of RAPT Therapeutics (RAPT) in Q2 2020, closing a stake of 33,409 shares — an estimated $5.68M sold.

Luminus Management first reported a position in RAPT in Q1 2020 and held it in 1 quarter. The position peaked at $5.68M in Q1 2020. 54 funds tracked by Wall St. Rank hold RAPT as of Q2 2020.

  • Luminus Management reported no remaining RAPT Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Luminus Management sold 33,409 RAPT Therapeutics shares in Q2 2020, an estimated $5.68M.
  • Luminus Management first reported a position in RAPT Therapeutics in Q1 2020 and held it in 1 quarter.
  • Luminus Management's RAPT Therapeutics position peaked at $5.68M in Q1 2020.
  • 54 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2020.

Based on Luminus Management's 13F filing for Q2 2020, filed 14 Aug 2020.